Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
Receive an email update when we add a new WEIGHT LOSS article.
The Latest on: Methotrexate and cyclophosphamide
via Google News
The Latest on: Methotrexate and cyclophosphamide
- The Challenges of Individualized Care for Older Patients With Localized Breast Canceron February 20, 2021 at 4:00 pm
 The trial tested the non-inferiority of capecitabine as compared with standard adjuvant chemotherapy cyclophosphamide, methotrexate and fluorouracil (CMF) or doxorubicin and cyclophosphamide ...
- HIV-related Lymphomaon February 19, 2021 at 4:00 pm
BEMOP: Bleomycin, etoposide, vincristine, methotrexate and prednisolone; CA: Cyclophosphamide and doxorubicin; CDE: Cyclophosphamide, doxorubicin and etoposide; CHOP ...
- Arthritis Foundation Lists Top 10 Arthritis Advances In 2004on February 9, 2021 at 4:01 pm
In 2004, researchers demonstrated that a brief course of treatment with rituximab, either alone or in combination with methotrexate or cyclophosphamide, was well tolerated, had an acceptable ...
- Drugs & Medications A-Zon February 5, 2021 at 2:44 am
- Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapyon February 3, 2021 at 4:00 pm
We investigated whether cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer is associated with worse cognitive performance more than 20 years after treatment.
- Transplantation with unrelated bone marrow in leukaemic patients above 40 years of ageon February 2, 2021 at 4:00 pm
Conditioning consisted of cyclophosphamide (120 mg/kg) combined with 10 Gy total body irradiation. Immunosuppression was ATG or OKT3 for 5 days before transplantation and methotrexate combined ...
- Drugs & Medications A-Zon January 1, 2021 at 1:48 pm
37 medications found for disease of respiratory tract - wegener's granulomatosis Methotrexate LPF Solution Off Label RX 27 Reviews Cytoxan Solution, Reconstituted (Recon Soln) Off Label RX 19 ...
- CLYM19123 / AALL1731 / Angela Girvinon November 23, 2020 at 2:40 am
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma ...
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Canceron September 26, 2020 at 8:56 pm
In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four ...
via Bing News